User profiles for Maurizio Rainisio
 | Maurizio RainisioAbaNovus srl Verified email at abanovus.com Cited by 9578 |
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
…, A Frost, VF Tapson, DB Badesch, S Roux, M Rainisio… - The Lancet, 2001 - thelancet.com
Background Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
…, F Parent, G Garcia, P Hervé, M Rainisio… - Journal of the American …, 2002 - jacc.org
Objectives : We sought to determine the factors associated with long-term survival in patients
with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion. …
with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion. …
Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension
…, A Kronenberg, I Leconte, M Rainisio… - Journal of the American …, 2003 - jacc.org
Objectives : The purpose of this study was to investigate the effects of bosentan (125 or 250
mg twice daily) on echocardiographic and Doppler variables in 85 patients with World …
mg twice daily) on echocardiographic and Doppler variables in 85 patients with World …
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials
…, DJ Van Veldhuisen, J Lewsey, A Frey, M Rainisio… - Jama, 2007 - jamanetwork.com
ContextPlasma concentrations of the vasoconstrictor peptide endothelin-1 are increased in
patients with heart failure, and higher concentrations are associated with worse outcomes. …
patients with heart failure, and higher concentrations are associated with worse outcomes. …
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on …
Background: The oral dual endothelin receptor antagonist bosentan improves exercise
capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its …
capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its …
Clinical trial design and new therapies for pulmonary arterial hypertension
…, MI Lewis, SC Mathai, M Rainisio… - European …, 2019 - Eur Respiratory Soc
Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on
case reports and small series, and was largely ineffectual. As a deeper understanding of the …
case reports and small series, and was largely ineffectual. As a deeper understanding of the …
[HTML][HTML] A cross-sectional and prospective cohort study of the role of schools in the SARS-CoV-2 second wave in Italy
S Gandini, M Rainisio, ML Iannuzzo… - The Lancet Regional …, 2021 - thelancet.com
Background During COVID-19 pandemic, school closure has been mandated in analogy to
its effect against influenza, but it is unclear whether schools are early COVID-19 amplifiers. …
its effect against influenza, but it is unclear whether schools are early COVID-19 amplifiers. …
New trial designs and potential therapies for pulmonary artery hypertension
…, TR Fleming, F Grimminger, M Rainisio… - Journal of the American …, 2013 - jacc.org
A greater understanding of the epidemiology, pathogenesis, and pathophysiology of pulmonary
artery hypertension (PAH) has led to significant advances, but the disease remains fatal. …
artery hypertension (PAH) has led to significant advances, but the disease remains fatal. …
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary …
…, R Krakover, I Kobrin, T Moriconi, M Rainisio… - Cardiology, 2008 - karger.com
Objective: Toevaluate the effects of bosentan on echo-derived hemodynamic measurements,
and clinical variables in symptomatic heart failure (HF) patients. Method: Multi- center, …
and clinical variables in symptomatic heart failure (HF) patients. Method: Multi- center, …
Tezosentan in patients with acuteheart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (ritz-4)
…, B Chandler, A Frey, I Kobrin, M Rainisio… - Journal of the American …, 2003 - jacc.org
Objectives : We sought to determine the effect of tezosentan in patients with acute
decompensated heart failure (HF) associated with acute coronary syndrome (ACS). Background : …
decompensated heart failure (HF) associated with acute coronary syndrome (ACS). Background : …
